Show simple item record

dc.contributor.authorKearney, Peter
dc.contributor.authorStokoe, Graham
dc.contributor.authorBreithardt, Gunter
dc.contributor.authorLongson, Carole
dc.contributor.authorMarco, Jean
dc.contributor.authorMorgan, John
dc.contributor.authorPriori, Silvia
dc.contributor.authorRuether, Alric
dc.contributor.authorTaylor, Rod
dc.contributor.authorHertog, Michael
dc.date.accessioned2012-02-03T15:05:48Z
dc.date.available2012-02-03T15:05:48Z
dc.date.issued2012-02-03T15:05:48Z
dc.identifier.citationEur Heart J. 2006 Apr;27(7):882-5. Epub 2006 Feb 13.en_GB
dc.identifier.issn0195-668X (Print)en_GB
dc.identifier.issn0195-668X (Linking)en_GB
dc.identifier.pmid16476691en_GB
dc.identifier.doi10.1093/eurheartj/ehi794en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208863
dc.description.abstractThe European Society of Cardiology (ESC) organized a one-day workshop with clinicians, health economic experts, and health technology appraisal experts to discuss the equity of patient access to novel medical technologies in Europe. Two index technologies were considered: implantable cardioverter defibrillators (ICDs) and drug-eluting stents (DES). The use of ICDs range from 35 implants/million population in Portugal to 166 implants/million population in Germany, whereas for implants of DES (as percentage of total stents) it is lowest in Germany at 14% and high in Portugal at 65%. These differences can in part be explained by a lack of structured implementation of guidelines, the direct cost in relation to the overall healthcare budget, and to differences in procedures and models applied by Health Technology Assessment (HTA) agencies in Europe. The workshop participants concluded that physicians need to be involved in a more structured way in HTA and need to become better acquainted with its methods and terminology. Clinical guidelines should be systematically translated, explained, disseminated, updated, and adopted by cardiologists in Europe. Clinically appropriate, consistent and transparent health economic models need to be developed and high-quality international outcome and cost data should be used. A process for funding of a technology should be developed after a positive recommendation from HTA agencies. Both the ESC and the national cardiac societies should build-up health economic expertise and engage more actively in discussions with stakeholders involved in the provision of healthcare.
dc.language.isoengen_GB
dc.subject.meshDefibrillators, Implantable/*supply & distributionen_GB
dc.subject.meshEuropeen_GB
dc.subject.meshHealth Services Accessibility/*standardsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMedical Laboratory Science/*standardsen_GB
dc.subject.meshPractice Guidelines as Topicen_GB
dc.subject.meshStents/*supply & distributionen_GB
dc.subject.meshTechnology Assessment, Biomedicalen_GB
dc.titleImproving patient access to novel medical technologies in Europe.en_GB
dc.contributor.departmentDepartment of Cardiology, Cork University Hospital Wilton, Ireland., peterkearney@eircom.neten_GB
dc.identifier.journalEuropean heart journalen_GB
dc.description.provinceMunster
html.description.abstractThe European Society of Cardiology (ESC) organized a one-day workshop with clinicians, health economic experts, and health technology appraisal experts to discuss the equity of patient access to novel medical technologies in Europe. Two index technologies were considered: implantable cardioverter defibrillators (ICDs) and drug-eluting stents (DES). The use of ICDs range from 35 implants/million population in Portugal to 166 implants/million population in Germany, whereas for implants of DES (as percentage of total stents) it is lowest in Germany at 14% and high in Portugal at 65%. These differences can in part be explained by a lack of structured implementation of guidelines, the direct cost in relation to the overall healthcare budget, and to differences in procedures and models applied by Health Technology Assessment (HTA) agencies in Europe. The workshop participants concluded that physicians need to be involved in a more structured way in HTA and need to become better acquainted with its methods and terminology. Clinical guidelines should be systematically translated, explained, disseminated, updated, and adopted by cardiologists in Europe. Clinically appropriate, consistent and transparent health economic models need to be developed and high-quality international outcome and cost data should be used. A process for funding of a technology should be developed after a positive recommendation from HTA agencies. Both the ESC and the national cardiac societies should build-up health economic expertise and engage more actively in discussions with stakeholders involved in the provision of healthcare.


This item appears in the following Collection(s)

Show simple item record